Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on Dyskinesia

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG) treatment has shown variable effect on dyskinesia in Parkinson's disease (PD). OBJECTIVE: To identify PD patients who are likely to have troublesome dyskinesia under LCIG treatment and describe the pharmacokinetic‐dynamic profile and dyskines...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mov Disord Clin Pract
Autors principals: Fabbri, Margherita, Zibetti, Maurizio, Calandra‐Buonaura, Giovanna, Contin, Manuela, Sambati, Luisa, Mohamed, Susan, Romagnolo, Alberto, Berchialla, Paola, Imbalzano, Gabriele, Giannini, Giulia, Rizzone, Mario G., Artusi, Carlo Alberto, Cortelli, Pietro, Lopiano, Leonardo
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604637/
https://ncbi.nlm.nih.gov/pubmed/33163564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.13068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars